Market Growth Driven by Increasing Drug Approvals, Advanced Technologies, Rising Chronic Disease Incidence, and Expanding Therapeutic Applica ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...

Sarepta Therapeutics Non-GAAP EPS of -$3.42 misses by $2.77, revenue of $744.9M beats by $60.78M SA NewsTue, May 06 11 Comments ...